Virtual Symposium:
COVID-19 Drug Discovery & Development
06 July 2020 | BST (UTC+1)

Join leaders, experts and scientists to accelerate COVID-19 drug discovery and development

The programme brings together international pharmaceutical organisations, biotech companies and academic institutions specialising in discovery, diagnosis and clinical development.

It includes over 20 cutting-edge presentations and workshops, over 8 hours of valuable networking sessions, over our digital networking platform.

Speaking Opportunities

We are looking to hear speakers working in discovery, diagnosis and clinical development related to COVID-19. Please contact Cerlin Roberts with your proposals.

Book Online

Online Booking for Virtual Symposium: COVID-19 Drug Discovery & Development is now open. Secure your place today!

LinkedIn Group

Stay up to date with the latest news and developments in our LinkedIn group dedicated to news and research relating to COVID-19 Drug Discovery & Development.

Programme

The Virtual Symposium includes...

Attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions working on COVID-19 Discovery and Development.

A look at the new modalities in discovery of therapeutic peptides, monoclonal antibodies and broad-spectrum antivirals

Hear the latest updates on the integration of screening and assay development approaches

Gain insights into modelling and computing techniques, AI and Bioinformatics tools

Explore successful development of point-of-care diagnostic tests, diagnostics tools and technologies for patient monitoring and treatment

Learn from Clinical Trial Development Updates for COVID-19

Engage with peers and selected leading providers in an interactive digital networking environment

Agenda at a Glance

Discovery Programs for COVID-19 Targets

  • Discovery of Novel Drug Targets
  • Potential repurposing candidates for COVID-19
  • The discovery of therapeutic peptides, monoclonal antibodies and broad-spectrum antivirals
  • COVID-19 vaccine candidate development
  • Enabling technologies in assay development and high throughput screening
  • Identifying molecules using modelling and computing techniques, AI and Bioinformatics tools
Diagnostic and Therapeutic Treatments
  • Collaboration to Develop COVID-19 Treatments
  • AI and their potential use in COVID-19 infection treatment
  • Development of plasma-derived therapy for COVID-19
  • Point-of-care diagnostic tests
  • Diagnostics tools and technologies for patient monitoring and treatment
Efficacy, Translation Clinical Trials Development
  • Testing for efficacy against COVID-19
  • Clinical Trial Development for COVID-19

Confirmed Speakers

The Symposium brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.

Mark Esser, AstraZeneca

Mark Esser

AstraZeneca

Pascal Falter-Braun, Helmholtz Zentrum

Pascal Falter-Braun

Helmholtz Zentrum

Mark Musen, Stanford University School of Medicine

Mark Musen

Stanford University School of Medicine

Patrick Aloy, IRB Barcelona

Patrick Aloy

IRB Barcelona

Purvesh_Khatri

Purvesh Khatri

Stanford University School Of Medicine

Event Features​

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of Series features and make the most of participation in a range of virtual experiences.

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Event App

Helping you get more from the event with opinion polls, networking features, searchable presentations & attendees, and much more

Digital Networking Opportunities

Connect directly with other registrants of event around the world